Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)

Naruto Taira; Kosuke Kashiwabara; Junji Tsurutani; Masahiro Kitada; Masato Takahashi; Hiroaki Kato; Yuichiro Kikawa; Eiko Sakata; Yoichi Naito; Yoshie Hasegawa; Tsuyoshi Saito; Tsutomu Iwasa; Tsutomu Takashima; Tomohiko Aihara; Hirofumi Mukai; Fumikata Hara

doi:10.1007/s12282-021-01296-z

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)

Naruto Taira, Kosuke Kashiwabara, Junji Tsurutani, Masahiro Kitada, Masato Takahashi, Hiroaki Kato, Yuichiro Kikawa, Eiko Sakata, Yoichi Naito, Yoshie Hasegawa, Tsuyoshi Saito, Tsutomu Iwasa, Tsutomu Takashima, Tomohiko Aihara, Hirofumi Mukai, Fumikata Hara

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication of the article, the Table 2 was published incorrectly with missing values. The corrected Table 2 is given in this correction. The original article has been corrected. (Table presented.).

Original language	English
Journal	Breast Cancer
DOIs	https://doi.org/10.1007/s12282-021-01296-z
Publication status	Accepted/In press - 2021
Externally published	Yes

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12282-021-01296-z

Fingerprint

Dive into the research topics of 'Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)'. Together they form a unique fingerprint.

Cite this

Taira, N., Kashiwabara, K., Tsurutani, J., Kitada, M., Takahashi, M., Kato, H., Kikawa, Y., Sakata, E., Naito, Y., Hasegawa, Y., Saito, T., Iwasa, T., Takashima, T., Aihara, T., Mukai, H., & Hara, F. (Accepted/In press). Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5). Breast Cancer. https://doi.org/10.1007/s12282-021-01296-z

Correction to : Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5). / Taira, Naruto; Kashiwabara, Kosuke; Tsurutani, Junji; Kitada, Masahiro; Takahashi, Masato; Kato, Hiroaki; Kikawa, Yuichiro; Sakata, Eiko; Naito, Yoichi; Hasegawa, Yoshie; Saito, Tsuyoshi; Iwasa, Tsutomu; Takashima, Tsutomu; Aihara, Tomohiko; Mukai, Hirofumi; Hara, Fumikata.

In: Breast Cancer, 2021.

Research output: Contribution to journal › Comment/debate › peer-review

Taira, N, Kashiwabara, K, Tsurutani, J, Kitada, M, Takahashi, M, Kato, H, Kikawa, Y, Sakata, E, Naito, Y, Hasegawa, Y, Saito, T, Iwasa, T, Takashima, T, Aihara, T, Mukai, H & Hara, F 2021, 'Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)', Breast Cancer. https://doi.org/10.1007/s12282-021-01296-z

Taira, Naruto ; Kashiwabara, Kosuke ; Tsurutani, Junji ; Kitada, Masahiro ; Takahashi, Masato ; Kato, Hiroaki ; Kikawa, Yuichiro ; Sakata, Eiko ; Naito, Yoichi ; Hasegawa, Yoshie ; Saito, Tsuyoshi ; Iwasa, Tsutomu ; Takashima, Tsutomu ; Aihara, Tomohiko ; Mukai, Hirofumi ; Hara, Fumikata. / Correction to : Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5). In: Breast Cancer. 2021.

@article{ea39141c643145fdab9dee3fd8ad66ec,

title = "Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)",

abstract = "In the original publication of the article, the Table 2 was published incorrectly with missing values. The corrected Table 2 is given in this correction. The original article has been corrected. (Table presented.).",

author = "Naruto Taira and Kosuke Kashiwabara and Junji Tsurutani and Masahiro Kitada and Masato Takahashi and Hiroaki Kato and Yuichiro Kikawa and Eiko Sakata and Yoichi Naito and Yoshie Hasegawa and Tsuyoshi Saito and Tsutomu Iwasa and Tsutomu Takashima and Tomohiko Aihara and Hirofumi Mukai and Fumikata Hara",

note = "Publisher Copyright: {\textcopyright} The Japanese Breast Cancer Society 2021",

year = "2021",

doi = "10.1007/s12282-021-01296-z",

language = "English",

journal = "Breast Cancer",

issn = "1340-6868",

publisher = "Springer Japan",

}

TY - JOUR

T1 - Correction to

T2 - Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)

AU - Taira, Naruto

AU - Kashiwabara, Kosuke

AU - Tsurutani, Junji

AU - Kitada, Masahiro

AU - Takahashi, Masato

AU - Kato, Hiroaki

AU - Kikawa, Yuichiro

AU - Sakata, Eiko

AU - Naito, Yoichi

AU - Hasegawa, Yoshie

AU - Saito, Tsuyoshi

AU - Iwasa, Tsutomu

AU - Takashima, Tsutomu

AU - Aihara, Tomohiko

AU - Mukai, Hirofumi

AU - Hara, Fumikata

PY - 2021

Y1 - 2021

N2 - In the original publication of the article, the Table 2 was published incorrectly with missing values. The corrected Table 2 is given in this correction. The original article has been corrected. (Table presented.).

AB - In the original publication of the article, the Table 2 was published incorrectly with missing values. The corrected Table 2 is given in this correction. The original article has been corrected. (Table presented.).

UR - http://www.scopus.com/inward/record.url?scp=85115645830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115645830&partnerID=8YFLogxK

U2 - 10.1007/s12282-021-01296-z

DO - 10.1007/s12282-021-01296-z

M3 - Comment/debate

AN - SCOPUS:85115645830

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

ER -

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer (Breast Cancer, (2021), 10.1007/s12282-021-01290-5)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this